ClinicalTrials.gg
CompletedNCT05843201Updated Dec 12, 2024

AquaPass Device in Treatment of CHF Patients

An interventional study of The AquaPass System in Chronic Heart Failure, Edema and CHF, sponsored by AquaPass Medical Ltd.. Completed at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Edema with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Edema · Israel.

Enrollment
9th of 11
18 · median 25
Started
2022
the only one that year
No phase
7 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
2 of 13
AquaPass Medical Ltd.

Among the 13 studies in Edema with a site in Israel, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 7 with no phase, and was the 12th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

1 of the 13 studies in Edema with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Edema with a site in Israel, or all of them as a file.
02

Study summary

The AquaPass System is intended for enhancing fluid transfer through the skin, by increased sweat rate, in fluid overloaded patients.

This study will examine safety, performance and usability of the AquaPass device in two phases:

Phase 1: Hospitalization treatment. Phase 2: Home/outpatient clinic treatment

Read the detailed description

The AquaPass System is intended for enhancing fluid transfer through the skin, by increased sweat rate, in fluid overloaded patients.

This study will examine safety, performance and usability of the AquaPass device in two phases:

Phase 1: Hospitalization treatment: This phase will begin when the patients are hospitalized with chronic heart failure symptoms and fluid overloaded and undergo sequential treatments. This phase will be conducted using a prospective case-control design, with measuring endpoint during hospitalization and follow-up (after discharge).

Phase 2: Home treatment: Upon investigator decision at discharge, patients will use Aqua-Pass device at home or at outpatient, after discharge, aiming to refine fluid management and prevent re-admission. This phase will require a separate Informed Consent Form (ICF) and will be conducted using a prospective single-group pre-post design.

  • A multi-center, prospective, open label, one arm study.
  • Chronic heart failure patients will be enrolled into the study when admitted to the hospital with fluid overload.
  • During the in-hospitalization treatment phase, patients will undergo up to 5 procedures with the Aqua-Pass device between 3-8 hours.
  • Following discharge and upon investigator decision, patients will sign a dedicated ICF and continue the Aqua-Pass treatments at home or in the outpatient clinic for up to 60 days, at a rate of 1-4 treatments per week.
  • Follow up assessments, either during visit or over the phone, 7±2 days from the last procedure
03

Conditions studied

  • Chronic Heart Failure
  • Edema
  • CHF

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18
  2. Subject was hospitalized for worsening of chronic heart failure with fluid overload.
  3. Recruitment with expectation for at least 2 additional days in hospital.
  4. Subject has composite congestion score ≥3.
  5. Baseline systolic blood pressure ≥100.
  6. Subject is capable of meeting the following study requirements:

    • Subject is taking a standing diuretic dose of ≥40 mg/day
    • For patients with \<30 kg/m2: baseline N-terminal pro b-type natriuretic peptide (NT-proBNP)>1,600 pg/ml
    • For patients with BMI >30 kg/m2: baseline N-terminal pro b-type natriuretic peptide (NT-proBNP) >800 pg/ml
    • For patients with rate-controlled persistent or permanent Atrial Fibrillation (AF): N-terminal pro b-type natriuretic peptide (NT-proBNP) >2,400 pg/ml.
  7. Subject completes 2 hours of run-in acclimatization session as follows:

    • Put on the wearable and see if the patient fits inside it comfortably.
    • Turn on console and see if the patient feels well when the skin temperatures are at least 37°C.
    • Blood Pressure, Heart Rate, Core Temperature and have not changed, relative to baseline, by more than 20%.
    • Systolic BP does not drop below 90 mmHg in 2 consecutive measurements.

Exclusion criteria

Exclusion Criteria:

  1. Subject is enrolled to another clinical investigation that might interfere with this study.
  2. Baseline systolic blood pressure \<100 mm Hg
  3. Subject considered to be in the acute worsening of the heart failure: Requiring ventilation, mechanical support or is clinically unstable requiring pressors, deterioration triggered by arrythmia, infection or other medical condition unrelated to fluid overload.
  4. Subject has any known lower body skin problems (open wounds, ulcers)
  5. Subject with severe peripheral arterial disease
  6. Subject is pregnant or planning to become pregnant within the study period, or lactating mothers.
  7. End-stage renal disease (\<15 ml/min/1.73 m2) or requiring dialysis.
  8. Inability or unwillingness to comply with the study requirements.
  9. History of heart transplant or actively listed for heart transplant or Left Ventricular Assist Device (LVAD).
  10. Implanted left ventricular assist device or implant anticipated \<3 months.
  11. or other noncardiac condition limiting to \<12 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Patients are hospitalized with chronic heart failure symptoms and fluid overloaded

    Phase 1: 'In Hospital' Phase: chronic heart failure (CHF) patients are enrolled in the study when admitted to the hospital with fluid overload. Study procedures performed, alongside diuretic therapy, in the hospital. Phase 2: 'At Home' Phase: Upon investigator's decision at discharge, the patients are enrolled in the second phase of the study for additional treatment sessions at home.

    Device: The AquaPass System

Interventions

  • DeviceThe AquaPass System

    The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.

06

What researchers measure

Primary outcomes

  1. Rate of in-hospital procedures with fluid loss from sweat of >500 ml/session

    The primary performance endpoint for the in-hospital phase is the amount of fluid loss from sweat per treatment procedure (\~4h); the target rate of sweat production is \>500 ml/session in the in-hospital phase.

    Time frame: In-Hospital Phase [2-10 days]

  2. Incidences of Device and treatment-related AEs and SAEs and symptomatic changes in vital signs

    Symptomatic changes in vital signs including incidences of symptomatic hypotension and a decrease of more than 50% in eGFR compared to baseline

    Time frame: up to 70 days

Secondary outcomes

  1. Change in body weight

    To assess the effectiveness of the AquaPass System during the treatment phase patients will be assessed for their weight prior to the first treatment and after the last treatment

    Time frame: Up to 60 days

  2. Change of diuretic therapy

    Documentation of changes in diuretics administration to assess safety and potential benefits with system use. (quantified by daily equivalent dose of furosemide).

    Time frame: Up to 60 days

  3. Changes in NT-ProBNP levels

    Changes in NT-ProBNP levels to demonstrate the system's safety and performance

    Time frame: Up to 60 days

  4. Rate of Hospitalizations or emergency visits for decompensated heart failure

    Documentation of CHF-related hospitalizations to assess safety and potential benefits with system use

    Time frame: Up to 60 days

  5. Changes in Renal function

    Changes in blood electrolytes that are correlated with worsening of renal function

    Time frame: up to 60 days

  6. Change of quality of life as assessed by the KCCQ-12

    Patients will be asked to complete the KCCQ-12 Questionnaire to evaluate their QoL during the study and assess the potential effect of the treatment on their well-being

    Time frame: Up to 60 days

07

Study locations

2 sites
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Rabin medical center, campus Belinson
    Petah tikva, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2023, 17 months.

Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2023
First posted
May 6, 2023
StartActual
Feb 20, 2022
Primary completionActual
Aug 14, 2023
CompletionActual
Dec 12, 2023
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843201
Lead sponsor
AquaPass Medical Ltd.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Feb 20, 2022
Primary completion
Aug 14, 2023
Completion
Dec 12, 2023
Last update
Dec 12, 2024

Study contacts

Doron Aronson, Prof.
principal investigator · Rambam MC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion